RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ -- IsoRay, Inc.
(NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced it will be featured as a presenting
company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September
10-12, 2017 at Lotte New York Palace Hotel in New York City.
Tom LaVoy, CEO of IsoRay, will provide an overview of the Company's business during the live
presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link
(www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is
confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 12:05pm Eastern Time
Location: Adams; Lotte New York Palace Hotel in
New York City
The presentation will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90
days following the live presentation.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more about this innovative Richland,
Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: our preliminary financial results for fiscal
2017 and the fourth quarter of 2017, the positive industry data fueling renewed interest in brachytherapy, strong patient
results, whether interest in and use of our products will increase or continue, whether the changes to the sales staff will
result in increased sales, whether further automation of production processes will be completed or will result in lower costs,
whether revenue will increase and costs decrease in the upcoming quarters, the perception by patients of quality of life
outcomes, and all other statements in this release, other than historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results
and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as an
audit of our financial results which may change our preliminary numbers, physician acceptance, training and use of our products,
our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient
quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to
enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies,
whether ongoing patient quality of life results with our products are favorable and in line with the conclusions of clinical
studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and
malignant diseases whether or not used in conjunction with other treatments, successful completion of future research and
development activities, whether we, our distributors and our customers will successfully obtain and maintain all required
regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO
standards as audited by BSI, the success of our sales and marketing efforts, the procedures and regulatory requirements mandated
by the FDA for 510(k) approval, changes in laws and regulations applicable to our products, the scheduling of physicians who
either delay or do not schedule patients in the periods anticipated, the use of competitors' products, less favorable
reimbursement rates, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so
by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content with multimedia:http://www.prnewswire.com/news-releases/isoray-announces-participation-at-the-19th-annual-rodman--renshaw-global-investment-conference-in-new-york-city-september-10-12-2017-300512047.html
SOURCE IsoRay, Inc.